Lifestyle Medicine and Gout in Viet Nam: Dietary Advice, Urate-Lowering Therapy, and Cardiometabolic Risk

Lifestyle Medicine and Gout in Viet Nam: Dietary Advice, Urate-Lowering Therapy, and Cardiometabolic Risk

Primary category: Evidence & Clinical Practice

Secondary category: Lifestyle Medicine in Viet Nam

Article type: VLMA Perspective

Last reviewed: October 30, 2026

A person experiencing a painful gout attack may be advised to avoid seafood, organ meats, and alcohol. They change their diet, drink more water, and take medication until the swelling improves. Several months later, another attack occurs. The same dietary advice is repeated, but no one has clearly explained whether long-term treatment is needed or what serum urate level should be achieved.

This illustrates a familiar difficulty in gout care. Diet and lifestyle matter, but gout is not simply the result of eating the wrong foods. It is a crystal-related inflammatory disease that can persist between attacks and, without appropriate management, lead to recurrent inflammation, joint damage, and reduced physical function.

Evidence-based Lifestyle Medicine can help people develop healthier behaviors and manage conditions that often accompany gout. However, dietary changes alone may not adequately control established disease. Medication also needs to be selected and monitored appropriately, particularly when gout occurs alongside chronic kidney disease, hypertension, diabetes, or cardiovascular disease.

For healthcare professionals in Viet Nam, effective care requires distinguishing elevated serum urate from established gout, understanding what dietary interventions can realistically achieve, recognizing when urate-lowering treatment is indicated, and addressing the broader health risks that frequently accompany the condition.

Elevated Serum Urate Is Not the Same as Gout

Gout develops when monosodium urate crystals accumulate in joints and surrounding tissues, triggering episodes of inflammation. Attacks often cause sudden, severe pain, swelling, redness, and marked tenderness. The joint at the base of the big toe is a familiar location, but gout can also affect the ankles, knees, wrists, fingers, and other joints.

Some people experience long periods without symptoms, while others develop increasingly frequent attacks, persistent inflammation, structural joint damage, or deposits of urate crystals known as tophi.

Serum urate plays a central role in the disease, but the relationship between urate concentration and clinical gout requires careful interpretation.

Genetic factors, kidney urate handling, body composition, medications, and other medical conditions influence serum urate levels. Many people with hyperuricemia never develop gout. Conversely, serum urate may fall during an acute attack and occasionally measure within the laboratory reference range.

A normal serum urate result during an attack therefore does not necessarily exclude gout, and an elevated result alone does not establish the diagnosis.

When the diagnosis is uncertain, identification of monosodium urate crystals in synovial fluid or material obtained from a tophus provides definitive evidence. Ultrasound or dual-energy computed tomography may also support diagnosis in selected circumstances.

Another important consideration is septic arthritis. An acutely swollen, painful joint should not automatically be attributed to gout, particularly when clinical findings raise concern about infection. Septic arthritis requires urgent assessment, and the presence of urate crystals does not completely exclude a coexisting joint infection.

These distinctions directly influence treatment decisions.

The 2020 American College of Rheumatology guideline conditionally recommends against initiating routine pharmacological urate-lowering therapy for asymptomatic hyperuricemia in people without previous gout attacks or subcutaneous tophi. [1]

This does not mean elevated serum urate should always be ignored. The person's clinical circumstances, associated conditions, and relevant treatment indications need to be assessed rather than automatically prescribing medication in response to a laboratory value.

What Does the Evidence Actually Say About Diet?

Dietary restriction is often one of the first measures recommended to someone diagnosed with gout.

There are biological reasons for this approach. Purines are metabolized into uric acid, while alcohol and certain dietary exposures can influence urate production, excretion, and the likelihood of acute attacks.

However, a plausible biological mechanism does not establish that a particular diet will reliably prevent gout attacks, eliminate existing crystal deposits, or replace urate-lowering medication.

The National Institute for Health and Care Excellence published its gout guideline in June 2022. The guideline states that there is insufficient evidence to establish that any specific diet prevents gout flares or effectively lowers serum urate. It recommends a healthy, balanced diet and recognizes that excess body weight and excessive alcohol consumption may worsen gout symptoms. [2]

This should not be interpreted as evidence that dietary habits have no influence on gout.

The American College of Rheumatology conditionally recommends limiting alcohol, purine intake, and high-fructose corn syrup in people with gout. However, the supporting evidence for these recommendations is generally of low or very low certainty. [1]

More recent research provides additional information.

A randomized controlled trial published in Nutrients in June 2026 investigated a structured low-purine, energy-restricted, nutritionally balanced diet in 90 people with gout. Over 42 days, the intervention improved serum urate and several metabolic measurements compared with routine nutritional education. [4]

The findings suggest that structured dietary intervention can produce measurable biochemical benefits. However, the study was relatively small and short, and the intervention involved several dietary changes together. Its results cannot establish which individual component produced the observed effects.

More importantly, the trial did not demonstrate whether the dietary approach reduces future gout attacks, prevents joint damage, or maintains its benefits over several years.

An improvement in serum urate after six weeks is not equivalent to long-term gout remission.

For healthcare professionals, the practical message is that dietary changes can support general health and may improve serum urate or associated risk factors. Their benefits should be communicated realistically, particularly to people who already have established urate crystal deposits.

Patients should not be led to believe that sufficiently strict eating habits will necessarily remove those deposits or make medically indicated urate-lowering treatment unnecessary.

Making Dietary Advice Practical in Viet Nam

Dietary counseling is more useful when it reflects how people actually eat rather than relying on generic lists of prohibited foods.

In Viet Nam, meals commonly include rice or noodles, vegetables, meat, fish, seafood, herbs, and sauces. Eating patterns vary between regions, households, and individuals. The type and quantity of food consumed, frequency of alcohol intake, and broader nutritional pattern may all be relevant.

Certain foods, including organ meats and some seafood products, contain substantial amounts of purines. Heavy alcohol consumption can also increase gout risk or contribute to attacks.

However, not all purine-containing foods have equivalent associations with gout.

Vegetables and legumes should not automatically be restricted in the same way as organ meats or certain animal-based foods. Broadly excluding nutritious plant foods solely because they contain purines may reduce dietary quality without providing a clear clinical benefit.

A more useful conversation begins with the person's overall eating pattern and the factors most relevant to their health.

For someone who regularly consumes large quantities of alcohol, reducing or avoiding alcohol may be an important priority. For another person, frequent sugar-sweetened beverages, excess energy intake, or substantial weight gain may be more relevant.

Where weight management is clinically appropriate, a balanced dietary pattern supporting gradual and sustainable weight reduction may improve several metabolic risk factors.

Meals emphasizing vegetables, whole grains, appropriate protein sources, and reduced consumption of highly refined or sugar-sweetened products may also help address hypertension, diabetes, and cardiovascular risk.

These benefits are important, but such dietary patterns should not be presented as proven substitutes for urate-lowering treatment in established gout.

Individual medical conditions can substantially change nutritional recommendations. People with chronic kidney disease, diabetes, malnutrition, or other clinical concerns may need specific adjustments to protein intake, energy intake, or fluid consumption.

Restrictive diets also deserve caution. Prolonged fasting, crash diets, and rapid weight-loss strategies may cause dehydration or abrupt metabolic changes that can worsen gout-related problems in some individuals.

Claims involving cherry products, vitamin supplements, herbal preparations, and commercially promoted gout diets should be evaluated critically. The evidence does not support presenting these products as established replacements for appropriate gout treatment.

For Lifestyle Medicine, the goal should not be to create the longest possible list of foods to avoid. It should be to help people maintain an appropriate dietary pattern that supports nutritional adequacy, metabolic health, and quality of life.

Physical Activity, Weight Management, and Hydration

Gout frequently occurs alongside obesity and other cardiometabolic conditions, but weight loss is not an appropriate universal treatment goal.

Some people develop gout without obesity. Others may be older, frail, or at risk of losing muscle mass. Their nutritional and functional needs differ from those of a younger person with obesity, hypertension, and newly diagnosed gout.

For patients who would benefit from weight reduction, gradual and sustainable changes are generally preferable to aggressive restriction.

Physical activity can support cardiovascular fitness, blood pressure management, glucose regulation, body composition, and long-term physical function. These benefits remain relevant even when direct evidence that exercise independently prevents gout attacks is less certain.

During an acute attack, significant pain and inflammation may temporarily restrict movement. Resting the affected joint and receiving appropriate treatment may be necessary before normal activity can resume.

Once symptoms improve, physical activity can be increased according to joint function, tolerance, and associated medical conditions.

Persistent pain, stiffness, or reduced mobility between attacks should not automatically be dismissed as a normal consequence of gout. Further clinical assessment may be needed, particularly when symptoms affect walking, work, or daily activities.

Hydration is another area where practical advice requires individualization.

Avoiding dehydration may be helpful, particularly in hot environments or during physically demanding work. However, recommending a fixed large volume of water to every patient is inappropriate.

People with heart failure, advanced kidney disease, or other conditions affecting fluid balance may require individualized medical recommendations.

These examples illustrate why Lifestyle Medicine should support safe and achievable behaviors rather than assume that identical recommendations suit everyone with gout.

When Urate-Lowering Therapy Becomes Necessary

A central question in gout management is when to begin long-term urate-lowering treatment.

Urate-lowering therapy addresses the biochemical conditions that allow monosodium urate crystals to accumulate. When serum urate is reduced sufficiently and maintained at an appropriate level, existing crystal deposits can gradually dissolve.

Over time, this can reduce recurrent attacks, improve disease control, and help resolve tophi.

This is different from treating the pain and inflammation of an individual gout attack.

The 2020 American College of Rheumatology guideline strongly recommends initiating urate-lowering therapy for patients with subcutaneous tophi, radiographic joint damage attributable to gout, or frequent attacks, generally defined as two or more per year. [1]

Treatment may also be considered in selected people with less frequent attacks or after a first attack when additional risk factors are present, including advanced chronic kidney disease, markedly elevated serum urate, or a history of kidney stones.

The NICE guideline similarly recognizes the importance of long-term urate-lowering treatment, although its recommendations differ somewhat in the circumstances in which treatment should be offered or discussed. [2]

These recommendations require clinical judgment. They do not mean that everyone with an elevated serum urate result should immediately receive medication.

However, when urate-lowering treatment is indicated, repeated dietary counseling should not become a reason to postpone effective treatment indefinitely.

A person may continue to have urate crystal deposits between attacks, even when joint pain has completely disappeared. Relying only on symptoms can therefore provide a misleading impression of disease control.

The clinical discussion should consider the diagnosis, frequency and severity of previous attacks, complications, associated conditions, medication safety, and the patient's preferences.

The question is not whether medication or lifestyle change is universally better. It is which combination of interventions is appropriate for the individual's condition.

The 2026 Evidence for Treat-to-Target Gout Management

Prescribing a urate-lowering medicine does not automatically mean that gout is adequately controlled. Treatment response needs to be assessed, and medication may require adjustment until an appropriate serum urate target is achieved.

Major international guidelines recommend a treat-to-target approach.

For most patients with established gout who require urate-lowering therapy, the usual serum urate target is below 360 micromoles per liter, equivalent to 6 milligrams per deciliter.

NICE recommends considering a lower target below 300 micromoles per liter, or 5 milligrams per deciliter, for patients with tophi, chronic gouty arthritis, or frequent ongoing attacks despite achieving the standard target. [2]

These are treatment targets for patients with gout in whom urate-lowering therapy is appropriate, not universal targets for everyone with asymptomatic hyperuricemia.

The value of this approach was examined further in the GO TEST Overture randomized clinical trial, published online in March 2026 and in the May 2026 issue of The Lancet Rheumatology. [5]

The trial enrolled 308 adults with gout at eight rheumatology centers in the Netherlands. Participants were assigned either to structured treatment guided by serum urate targets or to symptom-driven management without a predefined urate target.

Importantly, symptom-driven management did not necessarily mean receiving no urate-lowering medication. Treatment decisions were made according to symptoms and clinical judgment rather than systematic dose adjustment toward a specified serum urate concentration.

During months 18–24, gout remission occurred in 39.4% of participants assigned to treat-to-target care compared with 24.0% of those receiving symptom-driven management. The absolute difference was 15.4 percentage points.

Remission was assessed using a combination of outcomes, including the absence of gout attacks during the assessment period, no subcutaneous tophi, low patient-reported pain, and favorable patient assessment of disease activity.

This provides additional randomized evidence that systematic serum urate monitoring and medication adjustment can improve long-term gout control.

Nevertheless, the study was open-label and conducted in specialist settings. Its findings do not establish that every patient will achieve remission or that identical treatment arrangements are feasible in every healthcare system.

The clinical lesson remains important.

Relief from an acute attack is not the same as sustained control of the underlying disease. Follow-up should consider serum urate, recurrent attacks, tophi, physical function, treatment tolerance, and relevant clinical findings.

Patients should also understand that reaching the serum urate target is generally not a reason to discontinue treatment. When long-term urate-lowering therapy is indicated and well tolerated, maintaining the target commonly requires continued treatment.

Why Attacks May Continue When Treatment Begins

One challenging aspect of gout management is that attacks may occur during the first months after urate-lowering therapy begins.

As serum urate concentrations fall and existing crystal deposits undergo changes, acute inflammatory episodes can temporarily become more likely.

For a person starting medication intended to prevent future attacks, another painful episode can be discouraging. Without an adequate explanation, they may conclude that the medicine is ineffective or has made their condition worse.

This is why patient education and appropriate anti-inflammatory prophylaxis matter.

The American College of Rheumatology recommends concomitant anti-inflammatory prophylaxis for at least three to six months when urate-lowering therapy is initiated, with further assessment according to the person's clinical course. [1]

Colchicine or another appropriate anti-inflammatory treatment may be considered, depending on kidney function, gastrointestinal risks, interactions with other medicines, and associated conditions.

International guidelines also differ on the preferred timing of urate-lowering treatment initiation.

The American College of Rheumatology conditionally recommends beginning treatment during an acute flare when urate-lowering therapy is indicated, rather than necessarily waiting for the attack to resolve.

NICE generally recommends starting treatment two to four weeks after a flare has settled, while allowing initiation during an attack in people experiencing frequent flares. [1,2]

These differences should be interpreted through clinical judgment rather than applied mechanically.

An acute attack also does not ordinarily require stopping an established urate-lowering medicine. The inflammation should be managed appropriately while the long-term treatment plan is reviewed, unless a medication safety concern or another clinical reason requires a different decision.

Clear explanations can help patients understand why treatment continues even when pain is absent and why an early flare does not necessarily mean that long-term treatment has failed.

Allopurinol Safety Has Particular Relevance in Viet Nam

Allopurinol is commonly used for long-term urate lowering and is recommended as a preferred first-line treatment in several major international guidelines.

It can be effective and well tolerated, including in appropriately managed patients with chronic kidney disease. However, treatment initiation and dose adjustment require careful attention to safety.

A particularly serious concern is allopurinol-associated hypersensitivity, including severe cutaneous adverse reactions such as Stevens–Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms.

These reactions are uncommon but can be life-threatening.

Risk is influenced by several factors, including genetic susceptibility, impaired kidney function, and the initial allopurinol dose.

The HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions. This association has been demonstrated in several Asian populations and is particularly relevant to treatment safety in Viet Nam.

A case-control study published in Arthritis Research & Therapy in August 2020 recruited Kinh Vietnamese patients in Ho Chi Minh City. The researchers found a strong association between HLA-B*58:01 and cutaneous reactions to allopurinol, including severe reactions. Other associated factors included impaired kidney function and higher starting doses. [6]

The study provides valuable Vietnamese evidence, although its case-control design does not directly establish the absolute probability that an individual patient will experience a severe reaction.

A living systematic review and meta-analysis published in Scientific Reports in August 2025, involving researchers affiliated with healthcare and academic institutions in Ho Chi Minh City, further examined the prevalence of HLA-B*58:01 and its association with severe allopurinol-related skin reactions across different populations. [7]

These findings reinforce the importance of considering genetic susceptibility when evaluating allopurinol safety.

The American College of Rheumatology conditionally recommends HLA-B*58:01 testing before allopurinol initiation in selected populations with higher genetic risk, including specified Asian ancestry groups and African American patients. [1]

However, genetic risk and the decision to establish a universal screening policy are different questions.

A pharmacoeconomic analysis concerning Viet Nam, published in Pharmacogenomics in 2023, evaluated the cost-effectiveness of HLA-B*58:01 testing to prevent Stevens–Johnson syndrome and toxic epidermal necrolysis associated with allopurinol. Under the study's assumptions and willingness-to-pay threshold, universal screening was not found to be cost-effective compared with the modeled alternative. [8]

This does not eliminate the clinical importance of genetic testing or establish that testing should never be used. The result depends on the assumptions, costs, risk estimates, and healthcare context included in the model.

Singapore's Agency for Care Effectiveness also distinguishes genetic susceptibility from the clinical and economic case for testing every patient. Its guidance, updated online in August 2026, does not recommend routine HLA-B*58:01 genotyping for everyone starting allopurinol in Singapore, while allowing consideration in selected higher-risk circumstances. [3]

These recommendations reflect different healthcare systems and patient populations. They should not be treated as automatically determining testing policy in Viet Nam.

For Vietnamese healthcare professionals, relevant considerations include ancestry, kidney function, previous medication reactions, genetic risk, alternative treatments, testing availability, and applicable local professional guidance.

A negative HLA-B*58:01 result does not guarantee that a severe drug reaction cannot occur.

Patients starting allopurinol should receive appropriate counseling about possible hypersensitivity reactions. A new rash during treatment warrants prompt medical assessment, particularly when accompanied by fever, mucosal lesions, blistering, or systemic symptoms.

Starting treatment at an appropriately low dose, increasing it gradually when indicated, and monitoring the patient's response and tolerance are also important safety measures.

The goal is not simply to prescribe a medicine that lowers serum urate. It is to achieve effective disease control while reducing avoidable treatment-related harm.

Febuxostat and Cardiovascular Safety

Febuxostat is another xanthine oxidase inhibitor used to lower serum urate.

It may be appropriate for selected patients, including some who cannot use allopurinol or for whom allopurinol is unsuitable. However, its cardiovascular safety has been the subject of important clinical research.

The CARES randomized trial, published in the New England Journal of Medicine in 2018, studied patients with gout and established cardiovascular disease. Febuxostat was noninferior to allopurinol for the primary composite cardiovascular outcome, but cardiovascular and all-cause mortality were higher in the febuxostat group. [9]

The trial also experienced substantial treatment discontinuation and loss to follow-up, complicating interpretation of its findings.

The FAST trial, published in The Lancet in 2020, reported different results. In its study population, febuxostat was noninferior to allopurinol for the primary cardiovascular outcome and was not associated with increased mortality. [10]

The trials differed in participant characteristics, study design, and treatment circumstances. Their results should not be simplified into either a claim that febuxostat is universally unsafe or an assurance that cardiovascular safety concerns have been completely resolved.

NICE recommends allopurinol as first-line urate-lowering treatment for people with gout who have major cardiovascular disease. [2]

Medication selection should therefore consider the patient's cardiovascular history, kidney function, prior treatment, contraindications, interactions, and preferences.

For healthcare professionals in Viet Nam, the approved indications, availability, and regulatory requirements for individual medicines must also be considered.

Patients should not independently switch between urate-lowering medicines based on general information about clinical trials.

Gout, Cardiovascular Disease, and Kidney Health

Gout frequently occurs alongside hypertension, obesity, type 2 diabetes, dyslipidemia, chronic kidney disease, and cardiovascular disease.

These associations are clinically important because accompanying conditions affect long-term health, treatment selection, and medication safety.

However, association does not automatically establish causation.

Observational research has linked elevated serum urate with cardiovascular and kidney outcomes. These findings do not prove that lowering serum urate with medication will prevent heart attacks, strokes, or progression of chronic kidney disease in every patient.

The ALL-HEART randomized trial, published in The Lancet in 2022, evaluated allopurinol in older adults with ischemic heart disease who did not have gout. It did not demonstrate a reduction in major cardiovascular outcomes compared with usual care. [11]

This finding does not undermine the established benefits of urate-lowering treatment for appropriately selected patients with gout. Rather, it illustrates the difference between treating gout and prescribing urate-lowering medication solely for cardiovascular prevention.

A review published in the European Heart Journal – Cardiovascular Pharmacotherapy in 2026 also examined epidemiological, genetic, and clinical trial evidence concerning serum urate and cardiovascular risk. It concluded that current evidence does not support routine urate-lowering treatment solely for cardiovascular prevention in asymptomatic hyperuricemia. [12]

The relationship between urate and cardiovascular health remains an area of active research, but potential biological effects should not be confused with established clinical indications.

For someone living with gout, the practical response is to assess and manage cardiovascular and kidney risks through appropriate clinical pathways.

Blood pressure, glucose regulation, lipid levels, kidney function, tobacco exposure, and relevant medical history may all require attention.

Medication review is equally important.

Diuretics and certain other medicines can influence serum urate, while kidney function affects the suitability and safety of treatments used for acute attacks and long-term urate lowering.

Nonsteroidal anti-inflammatory drugs may create kidney, gastrointestinal, or cardiovascular risks in susceptible patients. Colchicine toxicity may become more likely in people with impaired kidney function or when interacting medicines are used.

Allopurinol and febuxostat can also interact dangerously with certain immunosuppressive medicines, particularly azathioprine and mercaptopurine.

These considerations reinforce the need for clinical review rather than independent medication changes.

Lifestyle Medicine can support the management of shared risk factors, including excess adiposity, smoking, harmful alcohol consumption, and physical inactivity. Its role should complement established treatment of hypertension, diabetes, kidney disease, and cardiovascular disease.

The objective is not to manage every associated condition through serum urate reduction. It is to address the health problems the person actually has.

What Recent Research From Viet Nam Tells Us

Viet Nam has an established national clinical reference for gout within the Ministry of Health's Guidelines for Diagnosis and Treatment of Musculoskeletal Diseases, issued under Decision No. 361/QĐ-BYT on January 25, 2014. [13]

The document addresses gout diagnosis, management of acute attacks, long-term serum urate control, and prevention of recurrence and complications.

Because it was issued in 2014, its recommendations need to be considered alongside newer scientific evidence and applicable updated professional guidance.

The existence of this document does not mean that Viet Nam has formally adopted every subsequent recommendation from the American College of Rheumatology, NICE, or other international organizations.

More recent Vietnamese research provides insight into practical treatment challenges.

A prospective single-center study published in Joint Bone Spine in 2025 followed 100 Vietnamese patients with crystal-proven gout who were not receiving urate-lowering medication at enrollment. The study examined the addition of allopurinol, flare prophylaxis, and patient education to care that included traditional Vietnamese herbal treatment. [14]

Improvements were observed in several outcomes, including gout attacks, physical function, quality of life, and measures of urate crystal burden during follow-up.

However, the study did not include a randomized comparison group. It involved a selected group of patients with severe gout and preserved kidney function, and loss to follow-up affected interpretation.

The results support further research into practical gout care models in Viet Nam. They do not establish the independent effectiveness of the herbal treatment or determine precisely how much of the improvement was attributable to each component.

Another study, published in January 2026, examined 560 outpatient prescriptions for gout at Gia Dinh People's Hospital in Ho Chi Minh City. [15]

The researchers reported generally high rates of guideline-concordant prescribing for indications, medication combinations, and treatment duration, but identified opportunities to improve dose appropriateness and management of potential drug interactions.

Only 68.4% of prescriptions met the study's criteria for dose appropriateness. The proportion flagged for major potential interactions ranged from 19.3% to 30.0%, depending on the drug-interaction screening resource used.

These findings require careful interpretation. Interactions identified by electronic screening tools are potential medication safety concerns, not confirmed clinical adverse events.

The study was retrospective and conducted at one hospital, so its findings cannot establish prescribing quality across Viet Nam.

Nevertheless, it highlights the importance of medication review, pharmacist involvement, dose assessment, and treatment safety.

Together, these Vietnamese studies provide a useful perspective. Better gout care requires more than dietary advice. It also depends on appropriate diagnosis, effective long-term treatment, medication safety, and communication between healthcare professionals.

Making Gout Care More Consistent in Practice

For healthcare organizations, a practical opportunity is to integrate lifestyle-related support into established gout management rather than create a separate pathway operating independently of clinical treatment.

At diagnosis, the treating clinician should establish whether the person has gout, review previous attacks and possible complications, assess relevant medications, and identify associated conditions.

When urate-lowering treatment is indicated, the management plan should address the serum urate target, medication selection, monitoring, appropriate prophylaxis, and patient education.

Lifestyle-related assessment can then focus on the factors most relevant to the individual.

Someone with recurrent attacks and substantial alcohol consumption may benefit from targeted support to reduce drinking. Another person with gout, obesity, and diabetes may need coordinated nutritional and metabolic care. A patient with chronic kidney disease may require additional assessment when selecting and monitoring treatment.

These individuals do not need identical recommendations.

Healthcare professionals should also consider the circumstances that influence treatment continuity.

Some patients stop urate-lowering medication when their pain disappears because they do not understand why treatment continues between attacks. Others discontinue treatment after experiencing an early flare, believing that the medication has failed.

Treatment costs, adverse effects, limited access to follow-up, and competing responsibilities may create additional difficulties.

Clear communication about treatment expectations is therefore part of effective care.

Patients should understand the difference between medicines used to manage acute inflammation and those intended to maintain long-term serum urate control. They should know why monitoring continues after symptoms improve and which symptoms require urgent medical assessment.

Depending on the healthcare setting, physicians, pharmacists, nurses, clinical nutrition professionals, and other appropriately qualified personnel may contribute within their professional responsibilities.

Meaningful improvement should also be assessed through outcomes that matter to patients.

For someone receiving urate-lowering therapy, relevant measures may include serum urate control, attack frequency, resolution of tophi, treatment tolerance, physical function, and quality of life.

Fewer attacks may allow someone to walk comfortably, return to work reliably, sleep without pain, or participate more fully in family activities.

These improvements may be more meaningful than a laboratory value considered in isolation.

The aim is sustained disease control without unnecessary treatment burdens or avoidable medication-related harm.

Professional and Legal Considerations in Viet Nam

Lifestyle Medicine education can help healthcare professionals understand the role of nutrition, physical activity, weight management, and behavior change in supporting people with gout.

However, diagnosing gout, excluding septic arthritis, interpreting investigations, prescribing medication, and managing urate-lowering treatment are regulated clinical activities.

In Viet Nam, the Law on Medical Examination and Treatment No. 15/2023/QH15, as amended and reflected in Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026, provides the principal legal framework for medical examination and treatment. [16]

Professional responsibilities and scopes of practice are further addressed in relevant implementing regulations, including Circular No. 32/2023/TT-BYT, as amended by subsequent instruments, including Circular No. 25/2026/TT-BYT, effective August 15, 2026. [17]

The Law on Disease Prevention No. 114/2025/QH15, effective July 1, 2026, provides a broader statutory framework relevant to prevention and management of noncommunicable diseases and their risk factors. [18]

These legal instruments support attention to prevention and health promotion, but they do not establish Lifestyle Medicine education or certification as independent authorization to diagnose disease, prescribe medication, or provide regulated clinical services.

Healthcare professionals must act within their qualifications, professional responsibilities, and legally authorized scopes of practice.

International clinical recommendations may inform professional education and clinical decision-making, but they do not automatically become binding Vietnamese regulatory requirements.

The same distinction applies to pharmacogenetic testing.

Scientific evidence linking HLA-B*58:01 with allopurinol hypersensitivity does not, by itself, establish that every patient must undergo genetic testing under Vietnamese law.

The decision to test must consider clinical risk, relevant professional guidance, available resources, and applicable legal requirements.

Medical histories, laboratory results, genetic information, and other identifiable health data also require appropriate protection.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, establish relevant requirements for the processing and protection of personal data. [19,20]

For the Vietnam Lifestyle Medicine Alliance (VLMA), the appropriate contribution is professional education, scientific knowledge exchange, and support for evidence-informed clinical understanding.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It does not independently diagnose gout, prescribe treatment, interpret genetic tests for individual patients, or provide clinical follow-up through its educational publications.

Its role is to strengthen professional understanding without creating expectations that lifestyle education replaces clinical qualifications, healthcare facility authorization, or appropriate medical care.

Better Gout Care Requires More Than Better Eating Habits

Gout illustrates an important principle of evidence-based Lifestyle Medicine: healthier behaviors can improve health without necessarily being sufficient to treat every aspect of a disease.

Appropriate nutrition, physical activity, weight management when indicated, and reduction of harmful alcohol consumption can support general health and help address risk factors associated with gout.

However, established gout is a crystal-related inflammatory disease. When long-term urate-lowering treatment is indicated, effective management requires sustained serum urate reduction, appropriate monitoring, and attention to medication safety.

The evidence available in 2026 strengthens the case for treatment guided by clinically meaningful targets rather than relying only on whether joint pain has disappeared.

At the same time, elevated serum urate should not automatically lead to medication in someone without gout. The association between hyperuricemia and cardiovascular disease should not be mistaken for proof that urate-lowering medication prevents cardiovascular events.

For healthcare professionals in Viet Nam, the opportunity is to combine established clinical guidance, emerging local research, culturally appropriate lifestyle support, and coordinated management of associated conditions.

Patients need more than instructions to avoid particular foods. They need to understand their diagnosis, why treatment may continue between attacks, what outcomes are being monitored, and when their care plan should be reassessed.

The goal is not simply to lower a laboratory value or prevent the next painful attack. It is to achieve sustained control of gout, preserve physical function, address associated health risks, and reduce avoidable treatment-related harm.

That is where Lifestyle Medicine can make a meaningful contribution: not by replacing effective gout treatment, but by supporting healthier behaviors within comprehensive, evidence-based clinical care.

Selected References

1. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744–760. DOI: 10.1002/acr.24180.

2. National Institute for Health and Care Excellence. Gout: Diagnosis and Management. NICE Guideline NG219. June 9, 2022.

3. Agency for Care Effectiveness, Ministry of Health, Singapore. Gout: Achieving the Management Goal. ACE Clinical Guideline. 2023. Online resource last updated August 4, 2026.

4. Zhao T, Li S, Wu R, et al. Efficacy of a Low-Purine, Energy-Restricted and Balanced Diet on Hyperuricemia and Metabolic Profiles in Gout Patients: A Randomized Controlled Trial. Nutrients. 2026;18(13):2047. DOI: 10.3390/nu18132047.

5. Moses A, Oude Voshaar MAH, van Geel EH, et al. A Treat-to-Target Strategy Versus Symptom-Driven Management of Gout in the Netherlands (GO TEST Overture): A Multicentre, Open-Label, Pragmatic, Superiority, Randomised Controlled Trial. The Lancet Rheumatology. 2026;8(5)–e345. DOI: 10.1016/S2665-9913(26)00034-2.

6. Do MD, Mai TP, Do AD, et al. Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnamese: Results From a Case-Control Study. Arthritis Research & Therapy. 2020;22:182. DOI: 10.1186/s13075-020-02273-1.

7. Pham HT, Tran MH, Mai Hoang TV, et al. HLA-B*58:01 Genotyping Prevalence and the Association With Allopurinol-Induced Severe Cutaneous Adverse Reactions: A Living Systematic Review and Meta-Analysis. Scientific Reports. 2025;15:30742. DOI: 10.1038/s41598-025-16062-w.

8. Duong KNC, Nguyen DV, Chaiyakunapruk N, Nelson RE, Malone DC. Cost-Effectiveness of HLA-B*58:01 Testing to Prevent Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in Vietnam. Pharmacogenomics. 2023;24(13):713–724. DOI: 10.2217/pgs-2023-0095.

9. White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients With Gout. New England Journal of Medicine. 2018;378:1200–1210. DOI: 10.1056/NEJMoa1710895.

10. Mackenzie IS, Ford I, Nuki G, et al. Long-Term Cardiovascular Safety of Febuxostat Compared With Allopurinol in Patients With Gout (FAST): A Multicentre, Prospective, Randomised, Open-Label, Non-Inferiority Trial. The Lancet. 2020;396:1745–1757. DOI: 10.1016/S0140-6736(20)32234-0.

11. Mackenzie IS, Hawkey CJ, Ford I, et al. Allopurinol Versus Usual Care in UK Patients With Ischaemic Heart Disease (ALL-HEART): A Multicentre, Prospective, Randomised, Open-Label, Blinded-Endpoint Trial. The Lancet. 2022;400:1195–1205. DOI: 10.1016/S0140-6736(22)01657-9.

12. Borghi C, Fogacci F, Cicero AFG. Urate-Lowering Therapy in Cardiovascular Pharmacotherapy: From Mendelian Randomization Data to Cardio–Renal–Metabolic Risk Modulation. European Heart Journal – Cardiovascular Pharmacotherapy. 2026;12(5):410–420. DOI: 10.1093/ehjcvp/pvag042.

13. Ministry of Health of Viet Nam. Decision No. 361/QĐ-BYT Issuing the Guidelines for Diagnosis and Treatment of Musculoskeletal Diseases. January 25, 2014.

14. Bardin T, Nguyen QD, Bousson V, et al. Addition of Allopurinol to Traditional Vietnamese Medicine Shows Major Improvement of 100 Gout Patients in a Single Center One-Year Prospective Study. Joint Bone Spine. 2025;92(5):105889. DOI: 10.1016/j.jbspin.2025.105889.

15. Nguyễn Sĩ Long, Phạm Hồng Thắm, Nguyễn Thị Thu Hương. Nghiên cứu tình hình sử dụng thuốc điều trị gout trên bệnh nhân ngoại trú tại Bệnh viện Nhân Dân Gia Định. Tạp chí Khoa học Trường Đại học Quốc tế Hồng Bàng. 2026;(39):169–178. DOI: 10.59294/HIUJS2026021.

16. Office of the National Assembly of Viet Nam. Consolidated Document No. 26/VBHN-VPQH: Law on Medical Examination and Treatment. February 26, 2026.

17. Ministry of Health of Viet Nam. Circular No. 32/2023/TT-BYT Detailing Certain Articles of the Law on Medical Examination and Treatment, as amended, including by Circular No. 25/2026/TT-BYT effective August 15, 2026.

18. National Assembly of Viet Nam. Law on Disease Prevention No. 114/2025/QH15. December 10, 2025. Effective July 1, 2026.

19. National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. June 26, 2025. Effective January 1, 2026.

20. Government of Viet Nam. Decree No. 356/2025/NĐ-CP Detailing Certain Articles and Measures for Implementing the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.

Editorial and Professional Scope Note

This article presents the professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine in gout care, including dietary behaviors, urate-lowering treatment, medication safety, and cardiometabolic risk. It reflects scientific and regulatory information reviewed as of October 30, 2026.

The article is intended for professional information, education, and scientific knowledge exchange. It does not constitute an official clinical practice guideline, individualized medical advice, a diagnostic or treatment protocol, a medication prescription, a genetic testing recommendation for an individual patient, or an authoritative interpretation of Vietnamese law. The introductory clinical scenario is hypothetical and does not describe an actual VLMA clinical activity.

Lifestyle interventions may support general health and gout management but must not delay or replace necessary assessment of acute joint inflammation, medically indicated urate-lowering treatment, or appropriate management of associated conditions.

Decisions concerning allopurinol, febuxostat, colchicine, anti-inflammatory medicines, genetic testing, treatment targets, dose adjustment, and monitoring require individualized clinical assessment by appropriately qualified healthcare professionals.

References to international guidelines do not imply automatic adoption as Vietnamese regulatory requirements or establish the local approval, availability, reimbursement, or suitability of any particular medicine or intervention.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed medical examination or treatment facility, medical licensing authority, or healthcare accreditation organization. VLMA does not independently diagnose gout, prescribe medication, conduct genetic testing for individual clinical decisions, or provide individualized medical follow-up.

Clinical assessment, treatment, prescribing, and follow-up must remain under the responsibility of appropriately authorized healthcare professionals and facilities within their lawful scopes of practice. Patient and genetic information must be handled in accordance with applicable confidentiality and personal data protection requirements.

Scientific publications and professional recommendations are included for educational purposes. Their inclusion does not imply that VLMA has formally adopted, clinically implemented, evaluated, validated, or certified any gout treatment or Lifestyle Medicine program discussed in this article.